Pharma/Payer Deals: 2011 Saw Important Step In Shift To Value-based R&D

Three major drug makers inked broad alliances with the research departments of major US payers in 2011. The alliances signal that even as pharma reorients its R&D engines to be more flexible and externally focused in the hopes of shedding risk and cost, such moves are not enough.